US FDA approves Celltrion’s Eydenzelt biosimilar referencing Eylea to treat wAMD, macular edema following RVO, DME and diabetic retinopathy: Incheon, South Korea Monday, October ...
FDA approves Celltrion's Eydenzelt, a new aflibercept biosimilar, enhancing treatment options for retinal diseases in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback